Hydrogenology
Source-linked study record

Molecular hydrogen-rhodiola as an adjuvant therapy for ischemic stroke in internal carotid artery occlusion: A case report

Chang FH, Lu JW, Hu CC, Jheng WL, Ka SM, Lin SZ, Hueng DY, Sung YF, Tsai YH, Tu JI, Ho YJ, Wang KY, Liu FC. · Open medicine (Warsaw, Poland). 2025;20(1):20251290.

HumanOther formsPublished 2025Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Human

Population or model

Human participants studied for other neurological conditions. See eligibility criteria in the linked full text.

Intervention and dose

Full text reports an oral H₂-generating preparation. Detected intervention quantities or schedules: 10 days, 2 months. · H₂-related quantities reported in the intervention passages: 10 days, 2 months. Values are not combined across different experimental arms.

Duration

10 days

Reported result

Article-reported result excerpt (24 words maximum): “On March 13, 2025, after two months of adjuvant therapy with hydrogen-rhodiola capsules, postoperative imaging demonstrated improved cerebral perfusion, correlating with the notable neurological…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Main limitation

Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Evidence and classification

What kind of evidence is this?

Evidence type

Human

Reported design

Case report

Research topic

Other neurological conditions

Administration form

Other forms

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

Human participants studied for other neurological conditions. See eligibility criteria in the linked full text.

Sample

Human study; the article does not state one consolidated sample total, so no total is inferred.

Duration

10 days

Intervention

Full text reports an oral H₂-generating preparation. Detected intervention quantities or schedules: 10 days, 2 months.

Hydrogen form

an oral H₂-generating preparation — H₂ only unless the full text explicitly reports oxygen co-delivery.

Dose or H₂ specification

H₂-related quantities reported in the intervention passages: 10 days, 2 months. Values are not combined across different experimental arms.

Comparator

Control or comparison condition reported in the full article; see the linked methods for arm-specific details.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury

Reported result

Article-reported result excerpt (24 words maximum): “On March 13, 2025, after two months of adjuvant therapy with hydrogen-rhodiola capsules, postoperative imaging demonstrated improved cerebral perfusion, correlating with the notable neurological…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Extraction completeness

The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Applies directly to

Applies only to the population and protocol reported in this other neurological conditions article.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 41141928 · DOI: 10.1515/med-2025-1290

Publisher access

A free full article is available through PubMed Central.

Extraction basis

Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.

Last reviewed

29 September 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.